CRL vs MRK
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
CRL presents a contradictory profile characterized by a very weak Piotroski F-Score of 2/9, indicating significant deterioration in fundamental financial health. While the company maintains a strong track record of beating earnings estimates and carries an attractive Forward P/E of 13.76, negative profit margins and declining YoY revenue and EPS growth are concerning. The valuation appears discounted (PEG 0.13), but the bearish technical trend and poor health score offset the bullish analyst consensus. Overall, the stock is a value play contingent on a fundamental turnaround that is not yet evident in the data.
MRK shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
CRL vs MRK: Head-to-Head Comparison
This page compares Charles River Laboratories International, Inc. (CRL) and Merck & Co., Inc. (MRK) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.